NFKB1 and diffuse large B-cell lymphoma: The dynamics of PIM1 mutations should be taken into account when treating patients with BTK inhibition, since PIM1-stabilizing mutations affect upstream regulators and downstream targets of the NF-kB pathway, decreasing sensitivity of ABC-type DLBCL to BTK inhibition [52].